Skip to content
10-Q

Quarterly Report

Mirum Pharmaceuticals, Inc. MIRM

0001759425-26-000037

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 60.98M sh
Shares Diluted Q1 2026 · Mar 31, 2026 58.85M sh
Shares Diluted Q1 2026 · Mar 31, 2025 48.89M sh
Capex Q1 2026 · Mar 31, 2026 $664K
Capex Q1 2026 · Mar 31, 2025 $41K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$228.76M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.96M
Short Term Investments Q1 2026 · Mar 31, 2026 $61.35M
Short Term Investments Q1 2026 · Dec 31, 2025 $86.64M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $324.91M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $296.68M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $211.82M
Stockholders Equity Q1 2026 · Mar 31, 2026 $242.49M
Stockholders Equity Q1 2026 · Dec 31, 2025 $314.69M
Stockholders Equity Q1 2026 · Mar 31, 2025 $233.26M
Stockholders Equity Q1 2026 · Dec 31, 2024 $225.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $272.82M
Current Liabilities Q1 2026 · Dec 31, 2025 $205.8M
Total Liabilities Q1 2026 · Mar 31, 2026 $648.42M
Total Liabilities Q1 2026 · Dec 31, 2025 $528.12M
Current Assets Q1 2026 · Mar 31, 2026 $569.44M
Current Assets Q1 2026 · Dec 31, 2025 $549.68M
Total Assets Q1 2026 · Mar 31, 2026 $890.92M
Total Assets Q1 2026 · Dec 31, 2025 $842.81M
Eps Diluted Q1 2026 · Mar 31, 2026 −$13.43
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.30
Eps Basic Q1 2026 · Mar 31, 2026 −$13.43
Eps Basic Q1 2026 · Mar 31, 2025 −$0.30
Sga Expense Q1 2026 · Mar 31, 2026 $96.33M
Sga Expense Q1 2026 · Mar 31, 2025 $57.71M
Net Income Q1 2026 · Mar 31, 2026 −$790.16M
Net Income Q1 2026 · Mar 31, 2025 −$14.68M
Operating Income Q1 2026 · Mar 31, 2026 −$789.47M
Operating Income Q1 2026 · Mar 31, 2025 −$15.18M
Revenue Q1 2026 · Mar 31, 2026 $159.88M
Revenue Q1 2026 · Mar 31, 2025 $111.59M